SecBot SecBot
6-K ·Filed May 27, 2026

AZN

ASTRAZENECA PLC
MIXED
Impact 6/10
Horizonweeks Processed5mo ago SEC0001654954-26-005381
Notable filing: 6-K
Actionable Insight ◆ Mixed

The PDUFA extension adds regulatory uncertainty but the EU positive opinion and pending ASCO data provide a potential catalyst on June 2, 2026. Traders should watch for the ASCO presentation and any subsequent FDA communication; the stock may remain range-bound until a new PDUFA date is announced.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$185.62
T+0 close · May 27, 2026 · via day close
Latest settled
−11.39%
T+60 · $164.48
Vs SPY
−13.01%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 27 $185.62entry
  2. T+1 · 6mo ago −0.15%α −0.70% · $185.34
  3. T+5 · 6mo ago −5.13%α −5.60% · $176.10
  4. T+20 · 5mo ago −1.40%α +0.90% · $183.02
  5. T+60 · 3mo ago −11.39%α −13.01% · $164.48

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

AstraZeneca announced the FDA extended the PDUFA date for camizestrant in HR+/HER2- advanced breast cancer to review additional data, including ctDNA clearance analyses to be presented at ASCO 2026. The FDA's advisory committee had previously failed to reach a majority vote in favor in April 2026, adding uncertainty; however, the EU's CHMP adopted a positive opinion on May 22, 2026, partially offsetting the delay. The extension introduces delay risk but is not a rejection, and the stock's historical negative drift on prior regulatory updates warrants a cautious view.

Key Facts

  • FDA extended PDUFA date for camizestrant NDA (SERENA-6) to review additional data, including ctDNA clearance outcomes
  • FDA's ODAC did not reach a majority vote in favor of the treatment strategy in April 2026
  • EU's CHMP adopted a positive opinion recommending approval on May 22, 2026
  • Camizestrant already approved in UAE and Saudi Arabia; regulatory reviews ongoing in Japan and other countries
  • ctDNA clearance data linked to longer-term efficacy will be presented at ASCO 2026 on June 2, 2026
  • Original PDUFA date was not disclosed; new date not specified

Financial Impact

Camizestrant targets a US addressable population of ~37,000 patients annually in 1st-line HR+/HER2- metastatic breast cancer with ESR1 mutations. Launch delay could affect peak sales estimates, though no specific revenue figures were provided.

revenuer&d timeline

Risk Factors

  • Extended review raises risk of Complete Response Letter (CRL) if additional data do not satisfy FDA concerns
  • FDA's April ODAC split vote signals unresolved efficacy/benefit questions
  • Competitive landscape (oral SERDs from Roche, Sanofi, etc.) continues to evolve during delay

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (36 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-005381
Document: 0001654954-26-005381-index-headers.html0001654954-26-005381
Document: 0001654954-26-005381-index.html0001654954-26-005381
Document: 0001654954-26-005381.txt0001654954-26-005381

Track record

77 reports on AZN

Performance horizon

19 of 38 bullish or bearish reports moved the stock their way by T+5. Best: +20.72% at T+60 after the Aug 17, 2026 report. 29 of 38 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Bullish 6/10 Entry price pending
  2. Nov 16, 2026today 6-K Bullish 6/10 Entry $185.55 Now $184.02 −0.82% settles Nov 23
  3. Nov 16, 2026today 6-K Bullish 6/10 Entry $185.31 Now $184.02 −0.70% settles Nov 23
  4. Nov 16, 2026today 6-K Bullish 5/10 Entry $185.09 Now $184.02 −0.58% settles Nov 23
  5. Nov 4, 202611d ago Institutional Cluster Mixed 3/10 Entry $186.85 to $184.38 Now $184.02 −1.51% ▼ −1.32% −4.61% vs SPY
  6. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
  7. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
  8. Oct 30, 202617d ago 6-K Neutral 5/10 Entry $186.65 to $186.43 Now $184.02 −1.41% ▼ −0.12% +2.59% vs SPY
  9. Oct 27, 202620d ago 6-K Bullish 5/10 Entry $170.08 to $183.88 Now $184.02 +8.20% ▲ +8.11% +10.10% vs SPY
  10. Oct 22, 202625d ago 6-K Bullish 6/10 Entry $172.57 to $173.46 Now $184.02 +6.63% ▲ +0.51% −0.19% vs SPY
Showing 10 of 77

US Market Status

Market Closed · Opens Tue (16h 42m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 27, 2026